Edgardo Santos, MD, FACP


Unmet Needs and Future Directions in the Management of CIM

July 22, 2022

Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.

Trilaciclib Efficacy in the Prevention of CIM in ES-SCLC

July 15, 2022

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.